CYANOTECH CORP (CYAN)

US2324373016 - Common Stock

0.44  -0.01 (-2.96%)

After market: 0.4499 +0.01 (+2.25%)

Fundamental Rating

1

Taking everything into account, CYAN scores 1 out of 10 in our fundamental rating. CYAN was compared to 36 industry peers in the Personal Care Products industry. CYAN has a bad profitability rating. Also its financial health evaluation is rather negative. CYAN does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CYAN has reported negative net income.
In the past year CYAN has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CYAN reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: CYAN reported negative operating cash flow in multiple years.

1.2 Ratios

CYAN has a worse Return On Assets (-16.95%) than 67.57% of its industry peers.
Looking at the Return On Equity, with a value of -33.40%, CYAN is in line with its industry, outperforming 43.24% of the companies in the same industry.
Industry RankSector Rank
ROA -16.95%
ROE -33.4%
ROIC N/A
ROA(3y)-0.63%
ROA(5y)-2.56%
ROE(3y)-1.54%
ROE(5y)-5.26%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 29.61%, CYAN is not doing good in the industry: 72.97% of the companies in the same industry are doing better.
CYAN's Gross Margin has declined in the last couple of years.
CYAN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.69%
GM growth 5Y-4.38%

More info and screens

1

2. Health

2.1 Basic Checks

CYAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYAN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CYAN has been increased compared to 5 years ago.
Compared to 1 year ago, CYAN has a worse debt to assets ratio.

2.2 Solvency

CYAN has an Altman-Z score of -0.42. This is a bad value and indicates that CYAN is not financially healthy and even has some risk of bankruptcy.
CYAN's Altman-Z score of -0.42 is on the low side compared to the rest of the industry. CYAN is outperformed by 78.38% of its industry peers.
CYAN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
CYAN has a Debt to Equity ratio (0.26) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z -0.42
ROIC/WACCN/A
WACC8.45%

2.3 Liquidity

CYAN has a Current Ratio of 1.44. This is a normal value and indicates that CYAN is financially healthy and should not expect problems in meeting its short term obligations.
CYAN has a Current ratio (1.44) which is comparable to the rest of the industry.
A Quick Ratio of 0.37 indicates that CYAN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.37, CYAN is doing worse than 89.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.44
Quick Ratio 0.37

More info and screens

0

3. Growth

3.1 Past

CYAN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -153.67%.
Looking at the last year, CYAN shows a very negative growth in Revenue. The Revenue has decreased by -13.23% in the last year.
CYAN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.44% yearly.
EPS 1Y (TTM)-153.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.63%
Revenue 1Y (TTM)-13.23%
Revenue growth 3Y-10.1%
Revenue growth 5Y-7.44%
Sales Q2Q%-5.23%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYAN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYAN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYANOTECH CORP

NASDAQ:CYAN (2/16/2024, 8:00:01 PM)

After market: 0.4499 +0.01 (+2.25%)

0.44

-0.01 (-2.96%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)02-08 2024-02-08/amc
Earnings (Next)06-25 2024-06-25/bmo
Inst Owners2.58%
Inst Owner Change-45.15%
Ins Owners44.58%
Ins Owner Change2.81%
Market Cap3.03M
Analysts0
Price TargetN/A
Short Float %0.06%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.13
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS3.26
BVpS2.01
TBVpS2.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.95%
ROE -33.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.61%
FCFM N/A
ROA(3y)-0.63%
ROA(5y)-2.56%
ROE(3y)-1.54%
ROE(5y)-5.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.69%
GM growth 5Y-4.38%
F-Score2
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.94%
Cap/Sales 1.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.44
Quick Ratio 0.37
Altman-Z -0.42
F-Score2
WACC8.45%
ROIC/WACCN/A
Cap/Depr(3y)62.42%
Cap/Depr(5y)45.28%
Cap/Sales(3y)3.5%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-153.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.63%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.23%
Revenue growth 3Y-10.1%
Revenue growth 5Y-7.44%
Sales Q2Q%-5.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-200.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-129.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.45%
OCF growth 3YN/A
OCF growth 5YN/A